1. Home
  2. Analysis
  3. Repatha
  4. Actemra

Repatha and Actemra drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Repatha (evolocumab) and Actemra (tocilizumab). Common drug interactions include acne among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Repatha and Actemra. It is created by eHealthMe based on reports of 38 people who take the same drugs from the FDA, and is updated regularly.

What is Repatha?

Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 156,254 Repatha users. Check the latest studies of Repatha.

What is Actemra?

Actemra has active ingredients of tocilizumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 102,759 Actemra users. Check the latest studies of Actemra.

On Mar, 13, 2026

38 people who take Repatha and Actemra together, and have interactions are studied.

Repatha and Actemra drug interactions.

What are the common drug interactions of Repatha and Actemra, by gender? *:

female:

  1. Acne (skin problems that cause pimples)
  2. Ear pruritus (pruritus or itching is ""the unpleasant skin sensation that frequently provokes scratching"" in ear)
  3. Pain
  4. Surgery
  5. Alanine aminotransferase increased
  6. Arthritis infective (purulent invasion of a joint by an infectious agent which produces arthritis)
  7. Aspartate aminotransferase increased
  8. Back pain
  9. Blindness
  10. Chronic kidney disease

male:

  1. Drug ineffective
  2. Dyspnoea (difficult or laboured respiration)
  3. Fatigue (feeling of tiredness)
  4. Myalgia (muscle pain)
  5. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

What are the common drug interactions of Repatha and Actemra, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Quality of life decreased
  2. Tardive dyskinesia (a disorder that involves involuntary movements)

60+:

  1. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  2. Arthralgia (joint pain)
  3. Chronic kidney disease
  4. Colitis ulcerative (inflammation of colon with ulcer)
  5. Dizziness
  6. Dyspnoea (difficult or laboured respiration)
  7. Exostosis (formation of new bone on the surface of a bone)
  8. Fatigue (feeling of tiredness)
  9. Injection site pain
  10. Knee arthroplasty

What are the existing conditions these people have? *

  1. Heart Attack: 4 people, 10.53%
  2. Temporal Arteritis (inflammation and damage to blood vessels that supply the head area): 3 people, 7.89%
  3. Polymyalgia Rheumatica (pain in many muscles): 3 people, 7.89%

* Approximation only. Some reports may have incomplete information.

Do you take Repatha and Actemra?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Repatha and Actemra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Repatha:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Actemra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Repatha and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Actemra and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on evolocumab and tocilizumab (the active ingredients of Repatha and Actemra, respectively), and Repatha and Actemra (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.